Pure Global AI
NCT04460131Recruiting

Soluble ST2 and Cardiovascular Outcome

Association Between Soluble ST2 and Cardiovascular Outcome After Cardiovascular Surgery
Nanjing Medical UniversityClinicalTrials.govdiagnostic test
Verified
Study focus
Disease/Condition
Cardiovascular Disease
Drug/Device/Intervention
soluble ST2
Study type
Observational
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Nanjing Medical University
Location
Nanjing, China
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2019
End date
Dec 31, 2021
Enrollment
500 participants
Primary outcome

All-cause mortality

Summary

Cardiac surgery induces hemodynamic stress on the myocardium, and this process can be
 associated with significant cardiovascular morbidity and mortality. Soluble suppression of
 tumorigenicity 2 (sST2) is biomarker of myocardial remodeling and fibrosis; however, little
 is known regarding their potential association with cardiovascular events. This study aimed
 to investigate the release of sST2 and its association with cardiovascular events undergoing
 cardiac surgery.

ICD-10 classifications
Cardiovascular disease, unspecifiedHypertensive heart diseaseHeart disease, unspecifiedAtherosclerotic cardiovascular disease, so describedAtherosclerotic heart disease
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04460131
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04460131 through Pure Global AI's free database. This phase not specified trial is sponsored by Nanjing Medical University and is currently Recruiting. The study focuses on Cardiovascular Disease. Target enrollment is 500 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.